CBD currently enjoys a more reassuring image than THC-rich cannabis. In France, its sale and consumption are legal because cannabidiol is not classified as a narcotic. However, this legality does not mean a complete absence of risk, particularly when it comes to roadside checks, saliva tests, or criminal liability.
The key point to understand is simple: during a drug test, it's not CBD that's being tested for, but THC. However, products sold as CBD can contain traces of THC, sometimes enough to be detected in saliva, blood, or urine. In other words, consuming a product labeled CBD doesn't guarantee you'll be safe from a positive test or the penalties that may follow.
CBD is legal in France, but within a specific framework
In France, the OFDT (French Monitoring Centre for Drugs and Drug Addiction) clearly states that CBD is not classified as a narcotic. Its sale and consumption are therefore legal. This distinction is important because it legally separates cannabidiol from THC, which remains the psychoactive substance primarily targeted by narcotics regulations.
This legality, however, should not be interpreted as a free pass. A product sold under the label “CBD” may have a different composition than expected. Consumers may therefore believe they are buying a legally authorized and “harmless” product, when in reality it contains detectable THC.
In practice, the risk stems not only from the legal framework applicable to CBD itself, but also from the actual composition of the oils, flowers, resins, infusions, or e-liquids on the market. This is where the gray area lies: a product that appears legal can expose its user to very real consequences, especially while driving.
Why a CBD product can lead to a positive test
The French Monitoring Centre for Drugs and Drug Addiction (OFDT) explicitly states that products sold as CBD may contain traces of THC. These traces can be detected in blood or urine, and potentially in saliva tests. The problem is therefore not theoretical: there is a real risk for the user, even when they believe they are consuming a compliant product.
This risk is compounded by labeling errors observed on the market. In an OFDT study conducted in 2022-2023, only a portion of the samples analyzed complied with the labeling. Even more striking, among the labeled products, only 19% actually corresponded to the stated composition, with a margin of error of 20%.
The study also shows that 12.5% of the samples analyzed had a Δ9-THC level exceeding 0.3%. This proportion even increased between 2022 (8%) and 2023 (14.5%). Therefore, simply purchasing an item labeled “CBD” does not guarantee accurate composition, the absence of THC, or the absence of legal risk.
Roadside checks: what the tests are really looking for
When it comes to roadside drug testing, law enforcement officers look for narcotics belonging to several families: cannabinoids, amphetamines, cocaine, and opiates. Therefore, testing isn't limited to cannabis, but with regard to CBD, the presence of THC is the main concern.
Saliva testing has become a key tool. The 2016 decree precisely outlines the procedures for screening using saliva or urine samples. For THC, the minimum saliva detection threshold is set at 15 ng/ml. Thus, if a CBD product contains THC, even in an amount not anticipated by the buyer, it can lead to a positive result.
It's therefore important to distinguish between two ideas: CBD is not the molecule sought after by roadside drug users, but a CBD product can be a source of THC exposure. It is precisely this discrepancy that creates confusion among many consumers, who believe they are legally safe because they haven't consumed "traditional" cannabis.
Driving after using drugs: a zero-tolerance policy
The French Road Safety Authority reminds the public that driving under the influence of drugs is prohibited, regardless of the amount consumed. Unlike alcohol, there is no comparable general public tolerance threshold for drugs. Once the use of substances classified as narcotics is established, a conviction can be filed.
This legal framework remains fully in force. The 2003 law concerning driving under the influence of narcotics is still listed as applicable on July 1, 2026, on Légifrance. The practical message is therefore clear: the fact that a product is sold legally does not automatically protect its user if a test reveals the presence of THC.
This zero-tolerance policy explains why caution is essential. Even a consumer acting in good faith, convinced they have used only legal CBD, can face legal action if the product they consumed contained THC. The debate then shifts from intent to the result of the test and the subsequent checks.
What are the penalties for a positive test?
The main penalties for driving under the influence of drugs are severe. Drivers face up to two years in prison and a €4,500 fine. In addition, six points are automatically deducted from their driving license, sometimes with immediate consequences for their professional and personal life.
Penalties are increased when drugs and alcohol are involved. In this case, the sentence can reach three years' imprisonment and a €9,000 fine. This increased penalty reflects the particular danger of combining several psychoactive substances while driving.
In the event of an accident causing bodily injury, the criminal consequences become even more severe. The penalty can be up to 5 years imprisonment and a €75,000 fine. These amounts demonstrate that the risk is not merely administrative or theoretical: it can very quickly escalate into serious criminal proceedings.
Refusing testing does not avoid punishment
When stopped by the police, some drivers believe that refusing to submit to a saliva or blood test might reduce the risks. This is false. Refusing to submit to testing carries the same penalties as driving under the influence of drugs.
In other words, refusing testing is not a protective strategy. Legally, this refusal is treated with the same severity as the suspected offense. The driver is therefore subject to the same penalties, without eliminating the initial suspicions.
This rule is important for CBD consumers who might fear a positive result due to a mislabeled product. Even in this scenario, resisting testing solves nothing. On the contrary, it worsens the procedural situation by eliminating any possibility of clarification through the analyses stipulated by the regulations.
The CBD market does not offer all the expected guarantees
The risk associated with CBD also stems from the still imperfect reliability of some non-pharmaceutical products. The OFDT 2022-2023 study highlights limited compliance with labeling requirements. For consumers, this means there is sometimes a significant discrepancy between what is stated on the packaging and what is actually in the product.
The fact that THC levels exceeding the 0.3% threshold were found in 12.5% of the samples is particularly telling. The increase observed between 2022 and 2023 shows that the problem cannot be dismissed as an isolated incident. It represents a market risk, and therefore a risk to the consumer.
Of particular note: products purchased in pharmacies were also included in the sample, and the OFDT found, in this small sub-sample, one in ten products containing more than 0.3% THC. Without drawing any general conclusions about the entire pharmacy network, this serves as a reminder that no purchasing channel can be considered an absolute guarantee of THC-free products.
CBD medications: a different situation, but not insignificant
In France, there are two cannabinoid-based medications listed by the OFDT (French Monitoring Centre for Drugs and Drug Addiction). The first is Epidyolex®, which contains cannabidiol with traces of THC and has had European marketing authorization since 2019. The second is Sativex®, which contains both THC and CBD.
Sativex®, however, was still not commercially available in 2024. This clarification is important because it shows that not all cannabinoid-based products fall under the same legal status. The legal frameworks and practical implications differ significantly between authorized medicines, wellness products, and recreational products.
However, even in the context of medication, the issue of THC remains. The presence of traces of THC in some treatments serves as a reminder that the problem of drug testing is not simply a matter of the legality of the product consumed. What matters during a test is also the substance actually detected.
Caution should therefore remain the rule for anyone considering driving after consuming CBD. The key message is simple: buying a product labeled “CBD” does not guarantee the absence of THC, and therefore does not guarantee the absence of legal risk while driving. Between imperfect labeling, the salivary THC detection threshold of 15 ng/ml, and a zero-tolerance policy, the exposure is real.
Beyond the penalty, the issue is also one of safety. Road safety authorities indicate that in 2019, 494 people were killed on the roads in accidents involving drugs, representing 23% of road fatalities. Before getting behind the wheel, it's therefore best to consider CBD with clear eyes: legal, yes, but not without risks in terms of detection and liability.
